Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IMA901

Vaccine (Peptide vaccine) · Immune activation, directed at tumor-associated peptide antigens expressed in renal cell carcinoma · developed by Immatics Biotechnologies GmbH

Phase 3 Most advanced trial (none active)
IMTX Developer
2 Registered trials

What is IMA901?

IMA901 is a multipeptide cancer vaccine made of 10 synthetic tumor-associated peptide antigens, nine binding HLA class I and one binding HLA class II. It is designed to increase cytotoxic T-lymphocyte responses against renal cell carcinoma cells expressing these peptides. It is studied in renal cell carcinoma and metastatic renal cell carcinoma, given with intradermal GM-CSF and cyclophosphamide in some regimens.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
tumor-associated peptide antigens expressed in renal cell carcinoma (antigen)
Mechanism
Immune activation, directed at tumor-associated peptide antigens expressed in renal cell carcinoma
Pathways
cytotoxic T-lymphocyte immune response
Therapy area
Oncology
Developer
Immatics Biotechnologies GmbH (IMTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01265901 Phase 3 Metastatic Renal Cell Carcinoma Completed IMTX
NCT00523159 Phase 2 Renal Cell Carcinoma Completed IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Renal Cell CarcinomaRenal Cell Carcinoma

More from Immatics Biotechnologies GmbH

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.

Follow IMTX, the company behind IMA901

See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.